These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16117313)

  • 21. The economic consequences of NSAID-induced gastropathy: the French context.
    de Pouvourville G
    Scand J Rheumatol Suppl; 1992; 96():49-53. PubMed ID: 1439624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost of radiotherapy versus NSAID administration for prevention of heterotopic ossification after total hip arthroplasty.
    Strauss JB; Chen SS; Shah AP; Coon AB; Dickler A
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1460-4. PubMed ID: 18234435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
    Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
    Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonsteroidal antiinflammatory drugs: benefit/risk evaluation in rheumatic diseases.
    Fenner H
    J Rheumatol Suppl; 1992 Jan; 32():98-9. PubMed ID: 1613741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of NSAIDs use in Palestinian mid-territories: a prospective study of ambulatory patients in outpatient pharmacies.
    Khdour MR; Hallak HO; Hejaz H; Shaeen M; Dweib M
    Curr Clin Pharmacol; 2014 Feb; 9(1):10-6. PubMed ID: 23343016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E; Toubouti Y; Hunsche E
    Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice.
    Moore N; Verschuren X; Montout C; Callens J; Kong SX; Bégaud B
    Therapie; 2000; 55(1):133-6. PubMed ID: 10860014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The unexpected side effects of new nonsteroidal anti-inflammatory drugs.
    Uzan A
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):687-8. PubMed ID: 16262557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
    McCarthy DM
    Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-steroidal antiinflammatory drugs. A review.
    Winzeler S; Rosenstein BD
    AAOHN J; 1998 May; 46(5):253-9; quiz 260-1. PubMed ID: 9652239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis.
    Singh G; Wu O; Langhorne P; Madhok R
    Arthritis Res Ther; 2006; 8(5):R153. PubMed ID: 16995929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people.
    Fosbøl EL; Gislason GH; Jacobsen S; Abildstrom SZ; Hansen ML; Schramm TK; Folke F; Sørensen R; Rasmussen JN; Køber L; Madsen M; Torp-Pedersen C
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):822-33. PubMed ID: 18383428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between prescribing nonsteroidal anti-inflammatory drugs and the potential prescription-related problems in a primary care setting.
    Dhabali AA; Awang R; Hamdan Z; Zyoud SH
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):851-61. PubMed ID: 23006441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal side-effects of NSAIDs in the community.
    Jones RH; Tait CL
    Br J Clin Pract; 1995; 49(2):67-70. PubMed ID: 7779646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals.
    Schüssel K; Schulz M
    Pharmazie; 2006 Oct; 61(10):878-86. PubMed ID: 17069430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs.
    Lane ME; Kim MJ
    J Pharm Pharmacol; 2006 Oct; 58(10):1295-304. PubMed ID: 17034651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
    Rahme E; Nedjar H; Bizzi A; Morin S
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.